tazarotene indications/contra

Stem definitionDrug idCAS RN
arotinoid derivatives 2571 118292-40-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tazarotene
  • tazorac
  • fabior
  • AGN-190168
a topical acetylenic retinoid; a topical kerytolytic
  • Molecular weight: 351.46
  • Formula: C21H21NO2S
  • CLOGP: 6.07
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 39.19
  • ALOGS: -5.67
  • ROTB: 5

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
June 13, 1997 FDA ALLERGAN

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Skin depigmentation 88.12 64.47 10 49 221 3385579
Application site discolouration 83.74 64.47 10 49 348 3385452

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC D05AX05 DERMATOLOGICALS
ANTIPSORIATICS
ANTIPSORIATICS FOR TOPICAL USE
Other antipsoriatics for topical use
FDA EPC N0000175607 Retinoid
FDA Chemical/Ingredient N0000007700 Retinoids
CHEBI has role CHEBI:50176 keratolytic drug
CHEBI has role CHEBI:50266 prodrug
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents
MeSH PA D009676 Noxae
MeSH PA D013723 Teratogens

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Psoriasis indication 9014002 DOID:8893
Acne vulgaris indication 88616000
Facial Hyperpigmentation indication
Benign Facial Lentigine indication
Facial Fine Wrinkling indication
Facial Hypopigmentation indication
Sunburn contraindication 23346002
Photosensitivity contraindication 90128006
Pregnancy, function contraindication 289908002

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.17 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Retinoic acid receptor beta Nuclear hormone receptor AGONIST EC50 9.10 CHEMBL CHEMBL
Retinoic acid receptor alpha Nuclear hormone receptor AGONIST EC50 7.20 CHEMBL CHEMBL
Retinoic acid receptor gamma Nuclear hormone receptor AGONIST EC50 7.40 CHEMBL CHEMBL

External reference:

scroll-->
IDSource
4021045 VUID
N0000148509 NUI
C0288792 UMLSCUI
6952 IUPHAR_LIGAND_ID
D01132 KEGG_DRUG
81BDR9Y8PS UNII
DB00799 DRUGBANK_ID
5542 MMSL
83947 RXNORM
108906007 SNOMEDCT_US
386935009 SNOMEDCT_US
4021045 VANDF
N0000006235 NDFRT
N0000148509 NDFRT
006668 NDDF
255259 MMSL
7328 INN_ID
5381 PUBCHEM_CID
CHEMBL1657 ChEMBL_ID
C086827 MESH_SUPPLEMENTAL_RECORD_UI
CHEBI:32184 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
TAZORAC HUMAN PRESCRIPTION DRUG LABEL 1 0023-0042 GEL 1 mg CUTANEOUS NDA 14 sections
TAZORAC HUMAN PRESCRIPTION DRUG LABEL 1 0023-8335 GEL 0.50 mg CUTANEOUS NDA 14 sections
TAZORAC HUMAN PRESCRIPTION DRUG LABEL 1 0023-9155 CREAM 0.50 mg CUTANEOUS NDA 17 sections
TAZORAC HUMAN PRESCRIPTION DRUG LABEL 1 0023-9156 CREAM 1 mg CUTANEOUS NDA 17 sections
AVAGE HUMAN PRESCRIPTION DRUG LABEL 1 0023-9236 CREAM 1 mg CUTANEOUS NDA 17 sections
Fabior HUMAN PRESCRIPTION DRUG LABEL 1 0145-0020 AEROSOL, FOAM 1 mg TOPICAL NDA 17 sections
Tazarotene HUMAN PRESCRIPTION DRUG LABEL 1 0713-0670 CREAM 1 mg TOPICAL ANDA 16 sections
Tazarotene HUMAN PRESCRIPTION DRUG LABEL 1 51672-1373 CREAM 1 mg TOPICAL ANDA 18 sections
Tazarotene HUMAN PRESCRIPTION DRUG LABEL 1 51672-1374 CREAM 1 mg TOPICAL ANDA 18 sections
FABIOR HUMAN PRESCRIPTION DRUG LABEL 1 51862-295 AEROSOL, FOAM 1 mg TOPICAL NDA 18 sections
Tazorac HUMAN PRESCRIPTION DRUG LABEL 1 54868-4456 GEL 1 mg ORAL NDA 14 sections
Tazarotene HUMAN PRESCRIPTION DRUG LABEL 1 60758-556 CREAM 0.50 mg TOPICAL NDA 17 sections
Tazarotene HUMAN PRESCRIPTION DRUG LABEL 1 60758-561 CREAM 1 mg TOPICAL NDA 17 sections